期刊
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
卷 23, 期 9, 页码 1447-1454出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.bbmt.2017.05.008
关键词
Autologous peripheral blood; stem cell transplantation; Matched unrelated donor bone marrow transplantation; Leukemia-free survival
资金
- Ministry of Education, Culture, Sports and Technology of Japan [15K09513]
- Ministry of Health, Labor, and Welfare of Japan [15eK0510002h0002, 15ek0109134h0001, 16mk0101065h0001]
- Bristol-Myers Squibb Foundation [21544355]
- Grants-in-Aid for Scientific Research [15K09513] Funding Source: KAKEN
Allogeneic stem cell transplantation (SCT) from an HLA-matched sibling donor (MSD) is a postremission treatment that offers a potential cure for adults with cytogenetically normal (CN) acute myelogenous leukemia (AML) in first complete remission (CR1). The best alternative in the absence of an MSD remains unclear, however. The aim of this study was to retrospectively compare the outcomes of autologous peripheral blood stem cell transplantation (auto-PBSCT; n = 177) and allogeneic bone marrow transplantation (BMT) from an HLA-matched unrelated donor (MUD; n = 173) in adult patients with CN-AML/CR1. Both the multivariate analysis (hazard ratio [FIR], 1.18; 95% confidence interval [CI], 0.71 to 1.97; P=.53) and propensity score models (HR, 1.40; 95% CI, 0.80 to 2.43; P=.24) indicated that the leukemia-free survival (LFS) rate of auto-PBSCT was not significantly different from that of MUD-BMT. These results suggest that in the absence of an available MSD, auto-PBSCT remains a viable alternative as postremission therapy in patients with CN-AML/CR1. (C) 2017 American Society for Blood and Marrow Transplantation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据